The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study

Changzheng Du,1 Yunfeng Yao,1 Weicheng Xue,2 Wei-Guo Zhu,3 Yifan Peng,1 Jin Gu1

ABSTRACT

Objectives: The prognostic significance of chemokine receptors in stage I/II colon cancer is unclear. We assessed the prognostic value of chemokine receptor CXCR3 and CXCR4 in stage I/II colon cancer.

Methods: 145 patients with stage I/II colon cancer who underwent curative surgery alone from 2000 to 2007 were investigated. Chemokine receptor expression was assessed by immunohistochemistry. The associations between CXCR3, CXCR4 and clinicopathological variables were analysed using the χ2 test, and the relationships between chemokine receptors and a 5-year disease-free survival were analysed by univariate and multivariate analyses.

Results: The high-expression rates of CXCR3 and CXCR4 were 17.9% (26/145) and 38.6% (56/145), respectively. There were no significant associations between the expressions of CXCR3, CXCR4 and clinicopathological factors including gender, age, tumour location, histological differentiation, pathological stage, lymphovascular invasion and pretreatment serum carcinoembryonic antigen (CEA). The 5-year disease-free survival was not significantly different between low-expression groups and high-expression groups of CXCR3 and CXCR4. Multivariate analysis revealed that serum CEA and a number of retrieved lymph nodes, rather than chemokine receptors, were independent prognosticators.

Conclusions: CXCR3 and CXCR4 are not independent prognosticators for stage I/II colon cancer after curative surgery.

BACKGROUND

The oncological outcome of patients with stage I/II colon cancer is favourable, with the 5-year survival rate exceeding 70%.1 2 Although curative surgery is sufficient for the majority of stage I/II patients, those with high-risk factors of recurrence require more treatment to reduce the risk of postoperative progression.1 3–5 The high-risk criteria are difficult to identify, since the currently acknowledged prognostic clinicopathological features are not optimal in guiding adjuvant therapy.6 7 Identifying prognostic markers for stage I/II colon cancer remains a significant clinical problem.

An increasing number of recent studies are focusing on the role of chemokines and chemokine receptors (CRs) in tumour progression.8 9 The interactions of chemokines and CRs are critical in promoting tumour migration and organ-specific metastasis.10–11 CXCR3 and CXCR4 have been demonstrated to be strongly related to tumour progression in advanced colorectal cancer.12–13 However, their prognostic value in stage I/II colon cancer is still unclear.

The aim of this study was to investigate whether CXCR3 and CXCR4 can be used as independent prognosticators for predicting the oncological outcome of stage I/II colon cancer.

PATIENTS AND METHODS

Patients

From a cohort of 860 consecutive patients with colon cancer who underwent curative surgery, 145 patients with stage I/II colon cancer who underwent curative surgery alone from 2000 to 2007 were investigated. Chemokine receptor expression was assessed by immunohistochemistry. The associations between CXCR3, CXCR4 and clinicopathological variables were analysed using the χ2 test, and the relationships between chemokine receptors and a 5-year disease-free survival were analysed by univariate and multivariate analyses.

Results: The high-expression rates of CXCR3 and CXCR4 were 17.9% (26/145) and 38.6% (56/145), respectively. There were no significant associations between the expressions of CXCR3, CXCR4 and clinicopathological factors including gender, age, tumour location, histological differentiation, pathological stage, lymphovascular invasion and pretreatment serum carcinoembryonic antigen (CEA). The 5-year disease-free survival was not significantly different between low-expression groups and high-expression groups of CXCR3 and CXCR4. Multivariate analysis revealed that serum CEA and a number of retrieved lymph nodes, rather than chemokine receptors, were independent prognosticators.

Conclusions: CXCR3 and CXCR4 are not independent prognosticators for stage I/II colon cancer after curative surgery.
After PBS rinses, sections were incubated at 37°C with a primary antibody for CXCR3 or CXCR4 for 1 h. Saline (PBS). The sections were then incubated at 37°C with a primary antibody for CXCR3 or CXCR4 for 1 h. All clinical and pathological data were available. Follow-up data were obtained from the institutional registration and follow-up database. Patients were followed regularly, with routine physical examination, serum carcinoembryonic antigen (CEA), colonoscopy surveillance, X-ray, ultrasonography and CT scans. We chose the end of the fifth year after surgery as the time-terminus. The primary end point (event) of this study was tumour progression including local recurrence and metachronous distant metastasis. Patients were treated as a censored observation if they outlived closure of follow-up without tumour progression.

All patients provided written, informed consent to agree to donate their tumour tissues for research.

**Pathological assessment**

For each case, sections of formalin-fixed and paraffin-embedded specimens were stained with H&E before optical microscopy examination by one of the authors. Standard pathological analysis was performed on all resection specimens. Each colonic tumour was restaged according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, seventh edition. Pathological features including histological differentiation, depth of tumour invasion and lymphovascular invasion were documented and reported. The number of retrieved lymph nodes was also recorded for each case as a potential prognostic factor for analysis. Macroscopic margins were assessed at surgery and microscopic margins were assessed histopathologically to ensure R0 resection.

**Immunohistochemistry**

All specimens were immunostained for CXCR3 and CXCR4 (1:100 dilution, R&D Systems, USA). Histological slices of 4 μm thickness were cut from the formalin-fixed, paraffin-embedded tumour tissues and mounted on cationic slides. After dewaxing and rehydration, sections were subjected to heat antigen retrieval in citrate buffer solution (pH 6.0) and heated for 3 min (103 kPa, 120°C). After cooling, 0.5% hydrogen peroxide was applied to block the activation of endogenous peroxidase, and sections were then rinsed five times with phosphate-buffered saline (PBS). The sections were then incubated at 37°C with a primary antibody for CXCR3 or CXCR4 for 1 h. After PBS rinses, sections were incubated at 37°C with a biotinylated secondary antibody (Zymed, USA) for 30 min and with avidin-biotin prediluted biotinylated complex for 10 min at room temperature. The antigenic sites were revealed by adding diaminobenzidine solution. The sections were then washed with distilled water, slightly counterstained with haematoxylin, dehydrated and mounted. The immunohistochemistry images of CXCR3 and CXCR4 are shown in figure 1.

Results were evaluated by one senior pathologist who was blinded to the patient clinical data. Expressions of CXCR3 and CXCR4 were assessed as positive if at least 1% of the tumour cells were clearly immunostained. The immunostaining intensity of CXCR3 and CXCR4 was classified as previously reported: negative, <1% of cells staining positive; weak staining (1–2+), 1–50% of cells staining positive and strong staining (3+), >50% of cells staining positive. The patients were categorised as high expression if the staining intensity was 3+, they were considered as low expression.

**Statistical analysis**

Data were analysed using the statistical software SPSS V.16.0 (SPSS Inc., Chicago, Illinois, USA). Differences between categorical variables were assessed using the χ² test. Survival curves were generated by the Kaplan–Meier method, and disease-free survival (DFS) rates were compared by the log-rank test. For the multivariate Cox proportional hazards regression analysis, a stepwise backward elimination method was used. p Values in this study were two-sided and p<0.05 was considered statistically significant in all univariate analyses, whereas p<0.1 has statistical significance in Cox proportional hazards regression for retaining in the equation.

**RESULTS**

**Patient baseline characteristics and expression of CXCR3 and CXCR4**

Of the 145 patients included, 84 were male and 61 were female. The mean age was 69 years (median 69; range 21–82). Median follow-up was 68.5 months (range 6–120). Ten patients (6.9%) were lost to follow-up and their data were included in the DFS analysis until the date of loss. The percentage of strong, weak and negative immunohistochemistry staining of tumour specimens was 17.9% (26/145), 52.4% (76/145) and 29.7% (43/145), respectively, for CXCR3; and 38.6% (56/145), 44.1% (64/145) and 17.2% (25/145), respectively, for CXCR4. There were no significant differences between patients regarding CXCR3 or CXCR4 expression for gender, age, tumour location, histological differentiation, T-stage, lymphovascular invasion and pretreatment serum CEA. High expression of CXCR4 was significantly more prevalent in patients with <12 retrieved lymph nodes than for patients with ≥12 retrieved lymph nodes (p=0.008), whereas there was no association between CXCR3 and the retrieved lymph node number. The
Figure 1  Immunohistochemical staining of CXCR3 and CXCR4 in primary colon cancer (original magnification ×200). Panel A and B illustrate high expression of CXCR3 and CXCR4, respectively. Panel C and D illustrate low expression of CXCR3 and CXCR4, respectively.

Table 1  Relationship between CXCR expression and clinicopathological variables

| Variable                        | n     | CXCR3 expression |               | p Value | CXCR4 expression |               | p Value |
|---------------------------------|-------|------------------|---------------|---------|------------------|---------------|---------|
|                                 |       | High (%) (n=26)  | Low (%) (n=119) |         | High (%) (n=56) | Low (%) (n=89) |         |
| Gender                          |       |                  |               |         |                  |               |         |
| Male                            | 84    | 18 (69.2)        | 66 (55.5)     | 0.198   | 33 (58.9)        | 51 (57.3)     | 0.847   |
| Female                          | 61    | 8 (30.8)         | 53 (44.5)     |         | 23 (41.1)        | 38 (42.7)     |         |
| Age (year)                      |       |                  |               |         |                  |               |         |
| <65                             | 58    | 7 (26.9)         | 51 (42.9)     | 0.133   | 19 (33.9)        | 39 (43.8)     | 0.237   |
| ≥65                             | 87    | 19 (73.1)        | 68 (57.1)     |         | 37 (66.1)        | 50 (56.2)     |         |
| Tumour location                 |       |                  |               |         |                  |               |         |
| Right side                      | 69    | 13 (50)          | 56 (47.1)     | 0.786   | 27 (48.2)        | 42 (47.2)     | 0.904   |
| Left side                       | 76    | 13 (50)          | 63 (52.9)     |         | 29 (51.8)        | 47 (52.8)     |         |
| Histological differentiation    |       |                  |               |         |                  |               |         |
| Well                            | 23    | 6 (23.1)         | 17 (14.3)     | 0.554   | 8 (14.3)         | 15 (16.9)     | 0.802   |
| Moderate                        | 95    | 14 (53.8)        | 81 (68.1)     |         | 39 (69.6)        | 56 (62.9)     |         |
| Poor                            | 17    | 4 (15.4)         | 13 (10.9)     | 0.786   | 5 (8.9)          | 12 (13.5)     |         |
| Mucinous and signet             | 10    | 2 (7.7)          | 8 (6.7)       |         | 4 (7.1)          | 6 (6.7)       |         |
| T-stage                         |       |                  |               |         |                  |               |         |
| T1-2                            | 25    | 5 (19.2)         | 20 (16.8)     | 0.945   | 9 (16.1)         | 16 (18.0)     | 0.529   |
| T3                              | 93    | 16 (61.5)        | 77 (64.7)     |         | 34 (60.7)        | 59 (66.3)     |         |
| T4                              | 27    | 5 (19.2)         | 22 (18.5)     |         | 13 (23.2)        | 14 (15.7)     |         |
| Number of retrieved lymph nodes |       |                  |               |         |                  |               |         |
| <12                             | 63    | 14 (53.8)        | 49 (41.2)     | 0.238   | 32 (57.1)        | 31 (34.8)     | 0.008   |
| ≥12                             | 82    | 12 (46.2)        | 70 (58.8)     |         | 24 (42.9)        | 58 (65.2)     |         |
| Lymphovascular invasion         |       |                  |               |         |                  |               |         |
| Yes                             | 10    | 1 (3.8)          | 9 (7.6)       | 0.691   | 4 (7.1)          | 6 (6.7)       | 0.926   |
| No                              | 135   | 25 (96.2)        | 110 (92.4)    |         | 52 (92.9)        | 83 (93.3)     |         |
| Serum CEA (ng/mL)               |       |                  |               |         |                  |               |         |
| <5                              | 90    | 15 (57.7)        | 75 (63.0)     | 0.612   | 35 (62.5)        | 55 (61.8)     | 0.932   |
| ≥5                              | 55    | 11 (42.3)        | 44 (37.0)     |         | 21 (37.5)        | 34 (38.2)     |         |

CEA, carcinoembryonic antigen.
demographic and clinicopathological characteristics are summarised in table 1.

**DFS analysis**
Postoperative tumour progression was seen in 27 patients. There were no significant associations between tumour progression and the expression of CXCR3 and CXCR4 (table 2). The 5-year DFS rate for all patients was 81.4%. No significant difference was found in DFS between CXCR3 high-expression groups and low-expression groups (76.9% and 82.4%, respectively; p=0.572; figure 2A), and CXCR4 (76.8% and 84.3%, respectively; p=0.248; figure 2B). Subgroup analysis revealed no significant differences of DFS with regard to CXCR3 expression with respect to tumour location, histological differentiation, tumour, node, metastases (TNM) stage, histological differentiation, lymphovascular invasion and pretreatment serum CEA. With respect to CXCR4, the only statistical difference of DFS in the well-differentiated subgroup was a significantly decreased 5-year DFS rate in patients with CXCR4 high-expression tumours (table 3).

**Multivariate analysis of DFS**
Clinicopathological variables were analysed using Cox proportional hazards regression, which involved gender, age, tumour location, histological differentiation, TNM stage, number of retrieved lymph nodes, lymphovascular invasion, pretreatment serum CEA, CXCR3 and CXCR4. Multivariate analysis showed that serum CEA and a number of retrieved lymph nodes were independently associated with DFS (table 4). CXCR3 and CXCR4 were not independent prognosticators for stage I/II colon cancer.

**DISCUSSION**
Chemokines are structurally related, small-polypeptide signalling molecules that bind to and activate a family of G-protein-coupled receptors.9 The interaction of chemokines and CRs are crucial in promoting tumour cell proliferation, angiogenesis and migration.9 14 15 High expression of CRs in malignant tumours is a strong prognosticator for disease progression and poor prognosis.16–18 With respect to colon cancer, in vitro and in vivo studies conducted within the past decade have confirmed the significance of CXCR3 and CXCR4 in tumour aggression and metastasis.12 19–21 CXCR3-specific ligands CXCL9 and CXCL10, as well as CXCR4 ligand CXCL12, secreted by distant organs including the liver and lung facilitate cancer cell metastasis and increase the risk of postoperative recurrence.12 21 22 However, most studies addressed advanced colon cancer, rather than early stage disease; studies concerning the prognostic significance of CR in stage I/II colon cancer are limited. The prognostic value of CR in stage I/II disease is significantly higher than that in stage III/IV colon cancer; whatever the CR status is, adjuvant chemotherapy would be mandatory for stage III/IV disease, while for stage I/II colon cancer
radical surgery may be the unique therapy since adjuvant chemotherapy could only benefit those patients with high-risk factors of tumour progression. Thus, if the expressions of CXCR3 or CXCR4 were proved to be risk factors for early stage colon cancer, they might become potential indicators for postoperative chemotherapy. Wu et al. once reported that although CXCR3 expression was strongly associated with distant metastasis and postoperative overall survival of colon cancer, it failed to demonstrate the prognostic value of CXCR3 for stage I/II disease. Kim et al. investigated CXCR4 expression in 125 patients including 57 with stage I/II disease. Although the study reported a correlation of the high expression of CXCR4 with increased tumour progression in stage I/II cancer, no definite conclusion was possible for several reasons. First, the sample size was too small to gain a reliable result. Second, this study examined rectal cancer and colon, whereas the treatment and prognosis of stage II rectal cancer are completely different with stage II colon cancer. The present study is the first to investigate the prognostic value of CXCR3 and CXCR4 in stage I/II colon cancer. A similar published study by Zhang et al. once mentioned that CXCR4 expression was closely associated with overall survival in stages II-III colon cancer, and it suggested that the coexpression of CXCR4 and CD133 was an efficient prognosticator. However, this study did not provide a further subgroup analysis to eliminate the prognostic value of CXCR4 in stage II patients. Our study demonstrated that CXCR3 and CXCR4 were not prognostic factors of postoperative tumour progression in stages II colon cancer. Although in the subgroup of well-differentiated tumour, patients with high expression of CXCR4 presented a tendency of decreased DFS, a

| Variable                  | High (%), n=26 | Low (%), n=119 | p Value | High (%), n=56 | Low (%), n=89 | p Value |
|---------------------------|----------------|----------------|---------|----------------|----------------|---------|
| Tumour location           |                |                |         |                |                |         |
| Right side                | 69 69.2        | 78.6           | 0.545   | 74.1           | 78.6           | 0.673   |
| Left side                 | 76 84.6        | 85.7           | 1.000   | 79.3           | 89.4           | 0.252   |
| Histological differentiation|               |                |         |                |                |         |
| Well                      | 23 83.3        | 82.4           | 0.938   | 62.5           | 93.3           | 0.049   |
| Moderate                  | 95 71.4        | 81.5           | 0.485   | 76.9           | 82.1           | 0.611   |
| Poor and Mucinous         | 27 83.3        | 85.7           | 0.904   | 88.9           | 83.3           | 0.714   |
| TNM stage                 |                |                |         |                |                |         |
| I                         | 25 100         | 90             | 0.470   | 88.9           | 93.8           | 0.673   |
| II A                      | 93 75          | 81.8           | 0.592   | 79.4           | 81.4           | 0.869   |
| II B                      | 27 60          | 77.3           | 0.573   | 61.5           | 85.7           | 0.150   |
| Lymphovascular invasion   |                |                |         |                |                |         |
| Yes                       | 10 100         | 88.9           | 0.705   | 100            | 83.3           | 0.439   |
| No                        | 135 76         | 81.8           | 0.606   | 75             | 84.3           | 0.203   |
| Serum CEA (ng/mL)         |                |                |         |                |                |         |
| <5                        | 90 93.3        | 90.7           | 0.687   | 85.7           | 94.5           | 0.149   |
| ≥5                        | 55 54.5        | 68.2           | 0.477   | 61.9           | 67.6           | 0.768   |

CEA, carcinoembryonic antigen; TNM, tumour, node, metastases.

| Variable                  | HR  | 95% CI      | p Value* |
|---------------------------|-----|-------------|----------|
| Gender                    |     |             |          |
| Male                      | 1   |             |          |
| Female                    | 0.614| 0.263 to 1.433 | 0.259   |
| Age                       |     |             |          |
| <65                       | 1   |             |          |
| ≥65                       | 1.009| 0.974 to 1.046 | 0.603   |
| Tumour location           |     |             |          |
| Right side                | 1   |             |          |
| Left side                 | 0.622| 0.279 to 1.390 | 0.247   |
| Histological differentiation|   |             |          |
| Well                      | 1   |             |          |
| Moderate                  | 2.19| 0.338 to 14.191 | 0.411   |
| Poor and Mucinous         | 0.909| 0.117 to 7.085 | 0.927   |
| TNM stage                 |     |             |          |
| I                         | 1   |             |          |
| II A                      | 1.246| 0.768 to 1.587 | 0.163   |
| II B                      | 2.431| 0.862 to 2.982 | 0.331   |
| Lymphovascular invasion   |     |             |          |
| No                        | 1   |             |          |
| Yes                       | 3.398| 0.453 to 25.497 | 0.234   |
| Number of retrieved lymph nodes |     |             |          |
| <12                       | 1   |             |          |
| ≥12                       | 0.955| 0.907 to 1.006 | 0.085   |
| Serum CEA                 |     |             |          |
| <5                        | 1   |             |          |
| ≥5                        | 4.516| 1.975 to 10.330 | <0.001  |
| CXCR3                     |     |             |          |
| High expression           | 1   |             |          |
| Low expression            | 1.1 | 0.422 to 2.869 | 0.845   |
| CXCR4                     |     |             |          |
| High expression           | 1   |             |          |
| Low expression            | 0.813| 0.362 to 1.830 | 0.618   |

*p<0.1 indicates statistical significance.

CEA, carcinoembryonic antigen; TNM, tumour, node, metastases.
definitive conclusion was not possible due to the ambiguous p value.

CXCR3 and CXCR4 have been considered as potential therapeutic targets in many studies. Several in vitro studies reported that inhibiting the interactions of chemokine and CXCR3 or CXCR4 using antibodies or small molecules significantly reduced the metastasis of colorectal cancer cells; this approach could become a promising therapy for colon cancer. However, the present results suggest that the antagonisms for CXCR3 and CXCR4 may not work on stage I/II disease, since the expressions of CXCR3 and CXCR4 did not affect postoperative DFS. On the other hand, the positive rates of these two CRs were significantly lower in stage I/II disease compared with stage III/IV disease. Admittedly, the present study has its own limitations of retrospective studies and is subject to patient selection biases. However, it provides important information that targeted treatment of CXCR3 or CXCR4 positive patients may be more appropriate for patients with advanced colon cancer.

In conclusion, CXCR3 and CXCR4 do not predict postoperative tumour progression in stage I/II colon cancer.

Contributors All authors have made a substantial contribution to this work and all have read and approved the final manuscript. CD and YY finished the paper and they made equal contribution. WX, W-GZ and YP provided technological support. JG designed the study.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

competing interests None.

Ethics approval This study was approved by Peking University Cancer Hospital ethics.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES

1. Wolpin BM, Meyerhardt JA, Mamon HJ, et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168–85.
2. Storl KE, Sondenaas K, Bukholm IR, et al. Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age. Int J Colorectal Dis 2011;26:1299–307.
3. Benson ABill, Schrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3406–19.
4. Zhou Z, Wu X, Wang R, et al. Optimal use of adjuvant chemotherapy in stage II colorectal cancer. Int J Colorectal Dis 2011;26:867–73.
5. Jonker DJ, Spithoff K, Maroun J. Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol) 2011;23:314–22.
6. Koebrugg Be, Vogelaar FJ, Lips DJ, et al. The number of high-risk factors resection for stage II colorectal cancer patients. Eur J Surg Oncol 2011;37:964–70.
7. O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381–4.
8. Vanderhellenne IM, Van Damme J, Stuif S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008;267:226–44.
9. Balkwill FR. The chemokine system and cancer. J Pathol 2012;226:148–57.
10. Fukunaga S, Maeda K, Noda E, et al. Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer. Oncology 2006;71:204–11.
11. Gassmann P, Hauer J, Schäfer K, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia 2009;11:651–61.
12. Wu Z, Han X, Yan J, et al. The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma. Biomed Pharmacother 2012;66:373–7.
13. Otsai A, Franco R, Aiello TA, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006;12:2796–803.
14. Murakami T, Kawada K, Iwamoto M, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 2013;132:276–87.
15. Oliveira FV, Rubie C, Ghadjar P, et al. Changes in CXCL12/CXCR4 expression during onset of colorectal malignancies. Tumour Biol 2011;32:189–96.
16. Kim J, Mori T, Chen S, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006;244:113–20.
17. Schmanski CG, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005;11:1743–50.
18. Ma X, Norsworthy K, Kundu N, et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 2009;8:490–8.
19. Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007;26:4679–88.
20. Cambien B, Karimjee BF, Richard-Fiardo P, et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 2009;100:1755–64.
21. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744–53.
22. Sakai N, Yoshihime H, Shida T, et al. CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer. Clin Exp Metastasis 2012;29:101–10.
23. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479–516.
24. Zhang NH, Li J, Li Y, et al. Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients. Exp Ther Med 2012;3:973–82.
25. Li JK, Yu L, Shen Y, et al. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol 2008;14:2308–13.